Ninth Circuit rejects class certification because ads differed

Cabral v. Supple LLC, — Fed.Appx. —-, 2015 WL 3855142,
No. 13–55943 (9th Cir. June 23, 2015)
 
The court of appeals vacated the certification of a class of
purchasers of a dietary supplement. The certified class was “[a]ll persons
residing in the State of California who purchased [the supplement] for personal
use and not for resale since December 2, 2007,” for the usual California
statutory claims.  The court of appeals
found that predominance was wanting, because it was “critical” that the
misrepresentation at issue be made to all class members.  The record here didn’t support a
determination that all the class members “saw or otherwise received” the
misrepresentation that the supplement was “clinically proven effective in
treating joint pain.” “While some deviations from precise wording in the
language of advertisements or representations might not be fatal to class
certification, advertisements that did not declare the [supplement] to be ‘clinically
proven effective in treating joint pain’ are a far cry from advertisements that
did.” The court of appeals expressed no opinion on whether a different class
could be certified.

from Blogger http://ift.tt/1HpQzR3

Posted in Uncategorized | Tagged , , | Leave a comment

claim of “improved” version of competitor’s product not likely to confuse

Arborjet, Inc. v. Rainbow Treecare Scientific Advancements,
Inc., 63 F.Supp.3d 149 (D. Mass. 2014)
 
Arborjet sued Rainbow over an alleged breach of a sales
agency agreement and won a preliminary injunction.  Arborjet makes insect and pest control
products for direct injection into trees. Rainbow makes pesticides to protect trees
and also distributes pesticides manufactured by other companies; it competes
directly with Arborjet.
 
In 2008, Arborjet began selling an emamectin benzoate
product, TREE-age, which protects trees from the emerald ash borer and other
destructive pests. TREE-age was successful, and Rainbow solicited Arborjet to
become its distributor of the full line of Arborjet’s products, including
TREE-age.  During negotiations, Arborjet
allegedly expressed concern about Rainbow’s possible copying of Arborjet’s
products, and Rainbow allegedly assured Arborjet that it had no such intention.  So they entered into a Sales Agency Agreement
and Rainbow agreed to devote its best efforts to the promotion and sale of
Arborjet’s products. 
 
The Agreement included a confidentiality and nondisclosure
provision, and said “in view of the confidential information regarding
Arborjet’s business affairs, plans, and necessities, [Rainbow] will not engage
in affairs intended to replicate the Arborjet’s products or processes.”  Plus, it had a noncompete provision that said
Rainbow wouldn’t “replicate the Arborjet system of using a plug which seals the
formulation in the xylem and a needle which injects behind the plug” for two
years after the agreement ended.  Arborjet
didn’t allege a breach of this last provision, but the parties disputed its
relevance to Arborjet’s breach of contract claim.
 
Instead, Arborjet alleged that Rainbow violated the part of
the agreement prohibiting Rainbow from “engaging in affairs intended to
replicate” its products.  Rainbow began
developing and testing ArborMectin, its competitor for TREE-age, as early as
2011, when the Agreement was still in force. 
(Rainbow terminated the Agreement in 2013.)  Arborjet didn’t allege that Rainbow used confidential
information, but said that didn’t matter. 
 
In 2014, Rainbow sent a blast marketing email to customers with
the subject line “Improved TREE-age! NEW ArborMectin Speed VIDEO.” The text said
that “Rainbow is excited to offer ArborMectin™, an improved 4% emamectin
benzoate (TREE-age) tree injection formulation. …Treat trees 30–70% faster
using ArborMectin™ versus TREE-age.”  The
email linked to a video that characterized ArborMectin as a replacement for
TREE-age and indicated that ArborMectin is “backed by science,” “proven to be
effective,” and treats trees “consistently faster than TREE-age.”
 
Arborjet argued that, while the Agreement was in effect,
Rainbow was contractually barred from engaging in “affairs intended to
replicate” Arborjet’s products, even absent misappropriation of Arborjet’s
proprietary confidential information. Moreover, Rainbow allegedly breached the
implied covenant of good faith and fair dealing given that it knew Arborjet’s
purpose in the Agreement was to stop copying.
 
Rainbow argued that it didn’t “replicate” TREE-age because
ArborMectin was not a “copy” or “duplicate.” Though the products have the same
active ingredient, ArborMectin is less toxic and has lower viscosity than
TREE-age. The court found this argument unpersuasive.  First, the fact that the final product had
differences didn’t matter, given that the contract covered activities “intended
to replicate” Arborject products. Given how Rainbow marketed the product as
“improved TREE-age,” the court found its activities covered. Plus, it was
unreasonable to read the contract as barring only exact copies “in light of
Arborjet’s particular, expressed concern about direct competition with its own
products.” Thus there was likely success on the merits of the contract claims.
 
Lanham Act false advertising: Arborjet argued that claims
that its product was “backed by science”, “proven effective” and “treats trees
30–70% faster than TREE-age” were establishment claims.  The tests Rainbow relied on were allegedly unreliable
because none of them was subject to peer review and the studies tested only
five or six trees whereas studies of TREE-age tested between 60 and 100 trees. Thus,
the study results didn’t prove the claim that ArborMectin was an improvement
over TREE-age. The court found that Arborjet hadn’t demonstrated the studies’
unreliability at this stage, without industry or regulatory standards regarding
peer review or sample size.  The claim
that ArborMectin was an “improved TREE-age” was a non-establishment claim, just
a general claim of superiority. Arborjet didn’t show actual falsity, because
ArborMectin had lower toxicity and viscosity than TREE-age and those
differences could be regarded as improvements.
 
However, the court expressed concern that the “improved
TREE-age” claim was likely to mislead customers into thinking the products came
from the same company. Rainbow indicated that it would no longer make that
claim.
 
Arborjet also argued that Rainbow’s website infringed
Arborjet’s registered trademarks “without including the symbol or any other
attribution to the owner,” which would cause customer confusion.  But, as Rainbow pointed out, none of the
other confusion factors favored Arborjet, such as the dissimilarity between TREE-age
and ArborMectin.  RT: Also, it has never
been the rule that failing to use a ® is misleading.  Unfortunately, the court also said that
Rainbow “should be more careful with its attribution of proprietary marks in
its communications,” even though Arborjet was unlikely to succeed on the
merits.  Rainbow should clearly be more
careful about suggesting that it produced an “improved version” of someone else’s
product—there are lots of ways of saying that which are nonconfusing—but
failing to use ® is not one of the ways in which it was careless.
 
Given Arborjet’s substantial likelihood of success on the
merits of the contract claim, it had less of a burden to show irreparable harm
under the First Circuit’s sliding scale. 
The court found irreparable harm because of the significant risk of
damage to Arborjet’s reputation and relationships with its consumers.  “Although plaintiff can be compensated for
lost profits by monetary damages, the effect on its goodwill and reputation are
particularly hard to quantify.”
 
The balance of equities tipped in Arborjet’s favor, but only
slightly given Rainbow’s investment in a new product.  Rainbow also argued that the public interest
favored competition and that this lawsuit would suppress competition, but “here
the parties voluntarily and knowingly contracted to limit their competition.”
Thus, it was in the public interest to enforce a limit on competition in this
case.

from Blogger http://ift.tt/1HpQzk7

Posted in Uncategorized | Tagged , , | Leave a comment

False patent marking isn’t material to business customers

Pactiv, LLC v. Multisorb Technologies, Inc., 63 F.Supp.3d
832 (N.D. Ill. 2014)
 
Pactiv and Multisorb compete to sell oxygen absorbers—“packets
of chemicals that react with moisture to absorb oxygen when placed inside food
containers,” keeping food fresher longer. The parties have sued each other for
patent infringement, and Multisorb also counterclaimed for tortious
interference and unfair competition and false advertising in violation of the
Lanham Act. Pactiv’s patent claims are currently stayed pending re-examination
before the PTO.  The court found that
prosecution history estoppel barred Multisorb from pursuing its doctrine of
equivalents-based patent claim, and therefore Multisorb lost its patent
infringement counterclaim.
 
The remaining counterclaims arose from a failed business
arrangement with Pactiv. Multisorb agreed to manufacture and sell oxygen
absorber packets to Pactiv for use in its fresh meat packaging system, the ActiveTech
System. The ActiveTech System is comprised of the ActiveTech Product (the
oxygen absorber packet), a “case ready” packaging system, and Pactiv’s methods
for packaging products. Shortly after the companies entered into a supply agreement,
Pactiv received a patent on a packaging system and a method for sealing and
preserving raw meat in a low or reduced oxygen environment. At Pactiv’s
request, Multisorb marked the oxygen absorber it supplied with a stamp
indicating that the product was protected under the patent.
 
Over ten years later, in 2008, the parties’ business
relationship soured after Multisorb began selling oxygen absorbers to Wal-Mart
and Wal-Mart vendors directly, taking business from Pactiv. Pactiv switched to
Dessicare to make a new oxygen absorber, continuing to mark the Dessicare
absorber with the Pactiv patent number.
 
Multisorb charged Pactiv with initiating “sham litigation”
against Multisorb with the intention of interfering with its prospective
business relationships. Internal Pactiv documents indicated that suing
Multisorb had business reasons more than IP-related reasons, and that Pactiv
desired to “tie [Multisorb] up” and force it to spend money.  But sham litigation relates to antitrust
claims, not tortious interference.  And
anyway Multisorb couldn’t prove sham litigation; even assuming Pactiv’s
statements indicated bad faith, the court couldn’t find that Pactiv lacked a
reasonable chance of success on the merits. Though its patents were recently
declared invalid in reexamination (a decision under appeal to the Federal
Circuit), there was nothing in the record to show that Pactiv would have known
of the invalidity at the time it sued. 
Thus, the tortious interference claim failed: “the mere filing of a
lawsuit cannot serve as a basis for a tortious interference claim when there
has been no showing that the litigant knew or should have known the case was
meritless or otherwise unjustified.”
 
As for false marking, Multisorb failed to show that Pactiv
intended to deceive the public by marking the oxygen absorber with its patent
number.  At best, the evidence showed
mere negligence: Pactiv “did not recall any discussions as to what patent
number to put on the Desiccare oxygen absorber” and Pactiv “did not have a
formal process in place to approve product covers.”
 
As for Multisorb’s Lanham Act counterclaim, Multisorb argued
that Pactiv misled customers by telling them that the ActivTech System was
protected by a patent when, in fact, it was not. However, Multisorb failed to
show deceptiveness or materiality.  “[N]one
of the customers deposed in this case indicated that they cared the least bit
whether the ActiveTech System was patent protected.”  The Executive VP/COO of one meatpacking
company testified that the existence of patents didn’t influence his decision
to use Pactiv’s system; the GM of another meatpacking company “testified
similarly that patents play no role in its purchasing decisions.”  Another customer witness didn’t recall any
discussion of patents relating to the system with Pactiv.  A final customer witness testified that
patent protection “didn’t really affect our decision-making process,” and
indicated that the validity of the patent wouldn’t have altered its buying
process.

from Blogger http://ift.tt/1Jj5FqQ

Posted in Uncategorized | Tagged , | Leave a comment

Trademark scholars roundtable: roles for the consumer in TM

Seventh Trademark Scholars Roundtable: The Construction of the Consumer in Trade Mark Law
 
Session 1: Roles for the Consumer in Trade Mark Law
What role does the “consumer” (whether “average” or “reasonable” or otherwise) play in trade mark law? Does consideration of the consumer simply help explain trademark law at some general level? Is the consumer useful merely to help legislators or policymakers shape the direction of trademark law? Is consideration of the consumer useful purposively to help determine outcomes in particular cases? Or is the trope of the consumer largely counterproductive? How should the answers to these questions inform doctrine? Are some doctrines more suited for analysis through the lens of the consumer than others? Importantly, are there trade mark doctrines where the consumer should have no (or only a limited) role in determining outcomes? If so, why, and what are they?
 
Introduction:   Jennifer Davis: Continuity and change with the average consumer in European law. Continuity: there’s a continuous question about the average consumer’s identity and role.  Change: Many will accept that the average consumer originally came via consumer protection law through classical economics: utility-maximizing rational actor. The law itself, EU Directive, also has a basis in neoclassical economics, most importantly so in the fact that any TM can be registered as long as it is acting as a TM.  These include marks that are purely descriptive in their startup; shapes; marks in limited supply such as colors.  Key that the question of whether the mark can be registered comes down to whether or not the average consumer sees it as distinctive. Confusing similarity also comes down to the average consumer.  Confusion inquiry also goes back to whether court thinks average consumer will perceive marks as particularly distinctive.  It’s the perceived views of the average consumer that delimit the amount of protection the EU will give to the mark. If TM is property, it is property defined by the supposed perceptions of the average consumer.
 
So what about when we aren’t talking about market efficiency but free riding or tarnishment?  Even here, law looks for average consumer.  ECJ has determined that tarnishment, dilution, free riding require the average consumer to make a link between the two marks at issue, as a way of delimiting extent of protection.
 
Change: It was not ever thus everywhere before the TM directive.  Whether or not TM received protection was seen as balancing act between TM owner, consumer, and competitors. Use perceived views of consumer to determine distinctiveness and confusion, but felt free to override consumer perception if in the public interest to do so. Huge change from that. Descriptive signs; colors; shapes; slogans: example is Kit-Kat/Have a Break.  1983 applied to register Have a Break as separate TM, though used with Kit-Kat name always. Court said it was irrelevant whether it was distinctive; it’s a term other traders might wish to use/it’s not used as a TM and thus can’t be registered. After the TM directive, went to CJEU, which said that a sign always used with a mark could be registered; never asked the question of public interest in leaving phrase free. Only question was whether average consumer saw it as distinctive.
 
Free market principles of TM directive: sometimes courts have tried to get around this by saying, for example, that average consumer is less likely to see shapes or colors as TM and registration is therefore resisted absent use.  Similar use of average consumer to limit scope of dilution. CJEU has looked at the functions of the mark, not just the origin function but investment, advertising, communication function—tried to reinject interest of competitors as well as consumers, by the back door.  Are we happy for the courts to use their own judgments as they used to before?  Remember competitors who may get lost if we only talk about average consumers.
 
Barton Beebe: Questions about consumers—very difficult to focus on one area without crossing over into others.  What the average consumer is; consumer as subject v. object of TM law.  Consumer as limiting restraint on TM law v. consumer as alibi for expansion of TM. Consumer as gauge of effective competition policy.  Consumer as political/liberal subject. 
 
Who is the agent in TM law?  Who is the active force, the subject, the thing engaging in self-initiated conduct?  More appealing to think of modern TM law as: the subject is the TM, searching for consumers.  We are trying to restore the human/the consumer: language is consumers constructing TM, not TM constructing consumers.  Not commodities floating around.
 
Europeans talked so much about average consumer, who speaks 24 languages—we know the consumer is not the moron in a hurry. More sophisticated: not an illiterate or abnormallystupid or ignorant.  Canadian case: relevant consumers would not be confused into purchasing the wrong nuclear reactor. That Homer Simpson might be confused is irrelevant.
 
Subject v. object: is TM law descriptive or normative? Is consumer the empirical anchor, measure of all things such as distinctiveness or confusion? Or is the consumer the object of TM law, who law tries to form or inform?  Raise consumer sophistication or allow it to decline? Maybe TM shouldn’t be as descriptive as it is in the US, where we like surveys.  Maybe we should accept some degree of confusion to achieve some other purpose. Consumer as endogenous, not exogenous; and changeable by TM law. Underneath this is the Q of circularity: is it true that the consumer internalizes implications of various TM cases, such as US Boston Hockey case or Arsenal in UK/Europe: consumers are trained to think that association is only allowed under licensing terms. But is that true? Does law have that much effect on consumer perception?
 
Orthogonal to this: is the consumer essentially just a source or target of general policy, and not any outcome under doctrine?  Dilution: does consumer perception matter?  Schecter would have preferred not, that it be an entirely grammatical/formal/linguistic theory that would never ask about whether consumers perceived an association.
 
TM scholarship: consumer as restraint on TM v. alibi for expansion—raised in readings. US: shift away from property concept of late 19thc. towards a consumer protection justification arguably licensed a massive expansion. Consumer is less a delimiter in US scholarship than the licensor of expansion, b/c consumer perception is malleable when you have good counsel. Also raises Q of materiality—seen as way to limit TM rights in the US, in tradition of American false advertising law. Is confusion material to decision to purchase? If not, won’t enjoin—but courts haven’t accepted it (largely).
 
Consumers and competition: one likes to dream of a shift in US law towards a competition focus. TM isn’t about minimizing search costs, but facilitating effective/socially optimal levels of competitions. TM restrictionists see competition as a way to find a limiting principle not based on vagaries of consumer protection. We should ask how the consumer would interact w/ TM as competition policy as compared to consumer protection policy.
 
Consumers and politics: consumers are citizens. Average consumer = average citizen. If we ascribe some degree of sophistication to them, these people are mostly voters, so that’s the liberal subject. We shouldn’t just think about competition policy but political ideology: how we conceive of subject of modern marketplace/political systems. Jennifer Davis: class consciousness among judges in English law of 19th c.—consumers were like servants; judges distinguished among classes of people. Today, instead, distinguish among classes of goods—looking at the commodity instead.
 
Primary Discussant:      Lionel Bently: Impact of registration on freedoms of other traders was much more central to pre-harmonized regimes. If trader would have a legitimate reason, without improper motive, to use a particular sign, then another trader should not get a registration/monopoly—geographical marks, etc.  So trader is another actor we could consider building a TM regime around. 
 
Trademark Directive/int’l legislation: term consumer isn’t present; it’s the “public” who is protected against likely confusion. Public is another concept around which we might build TM. What is at stake in the collapse of the public into the consumer?  Perhaps this notion of the citizen might be an alternative.
 
Weird things that go on in our use of “consumer” and in the assumptions that it causes us to carry with it.  Normally when we talk about consumer protection we’re concerned w/ a particular category of consumers regarded as vulnerable: lack the same level of info as businesses in the marketplace. Protection overcomes those perceived problems. In TM law that’s not the same consumer at all—the purchaser of nuclear reactors as well as of sweets.  But he’s concerned that we carry with us a different set of assumptions about chief characteristics of consumer—relative stupidity and vulnerability.
 
Distinction between consumer and citizen: Discomfort w/how Qs of inherent distinctiveness are assessed b/c starting point is that we are looking at signs that might qualify as TMs.  ECJ tends to say that when you’re assessing whether something is devoid of distinctive character/unregistrable, you use the POV of the consumer, and descriptive things are likely descriptive v. distinctive. But things that aren’t explicable to consumers are just assumed to be fodder for the TM system.  Any attribute of a product that can’t be explained immediately has the capacity to be a TM. That’s just weird. That’s not how I look at the world—that anything I can’t understand is a TM. So why should European TM law assume that the person who is looking at the world is only using one spectrum?
 
Stacey Dogan: Relationship between search costs & consumers & competition: reflect on the literature/case law that suggests that reducing search costs in itself is the goal of TM.  Appropriate use of search costs is not as goal in itself, but reducing search costs to promote competition. Better information in markets should promote reduction in search costs, but if you inhibit competition by granting rights you shouldn’t grant those rights.
 
Annette Kur: ECJ uses public interest concept, but divides it into public interest of consumer in identifying products; public interests of competitors to be able to use things they want to keep available. Slashed in two. It should be one concept. Cardinal mistake: not allowing you to look into the second prong except for descriptive signs. Needs to be in measurement of scope of protection granted, which was thrown out in Adidas where they said that part two of public interest was irrelevant in determining scope of mark. 
 
Competition also has a connection to the perception of those who operate in the market. These people don’t function in the way we picture the mind of the consumer to function.  It’s not (just) about diminished search costs.  We need to know much more about what’s happening in the impact of TM on consumers’ minds.  When people decide whether to buy, what’s going on?
 
RT: For Dogan: I saw a very subtle equivocation there: if you really believe that search costs is only a means toward the competitive end, shouldn’t you in each case balance the decrease in search costs from granting TM protection to a design with secondary meaning with the increase in monopoly profits in cases in which the design also has functionality? Sometimes mild functionality might not overwhelm the search cost benefit of protection as TM, unless you’ve already created a hierarchy of things that help competition. (ETA: Bob Bone discusses this issue; he believes in general rules though I understand him to want more inquiry into the balance of functionality and distinctiveness.)
 
Another possibility: the subtle influence of language.  Use of “the legislator” in Europe as indicating a more plausible bearer of intent than the US “the legislature” where the criticism that the legislature as a body does not regularly have a coherent or consistent intent has of late been extremely influential, as we saw in the recent health care case.  Use of the “average consumer” may have similar effects in smushing down the variation that we know exists—we want to see more understanding of variation and the common lack of coherent consumer “intent” or “belief” in the way the law assumes.  So maybe we should always be talking about consumers!
 
Dev Gangjee: you have to have an abstract concept, and that interacts with nationality.  Can we set up a pre-large national registration system understanding of consumers?  How do courts initially/historically treat the task of figuring out what large groups of consumers are likely to think?  Property plus scale may force us to reach for an abstraction.
 
Ilanah Simon-Phima: Everybody in European law talks a lot about the average consumer, but nobody does anything about him or her.  Nontraditional marks: our average consumer has stock reactions.  That may or may not be correct, but it’s a cut and paste job: from sound to color etc. This is an excuse. Blame things you don’t want to register on the consumer. Maybe rejection on relative grounds is doing something similar—Community TMs, courts take great pains to define average consumer in detail, but do nothing with it. Paragraph about what the average consumer is, and then the court doesn’t come back to it in the rest of the judgment.
 
Dirk Visser: agrees, the courts don’t like these TMs and then just create a consumer who doesn’t recognize them. Normatively he agrees, but they’re dressing up a normative decision in a factual way.
 
Robin Jacob: No, they’re right! Consumers are much more straightforward than this discussion says.  Consumers recognize smells but don’t think they’re TMs.  They love or hate smells/tastes, but not as TMs.  The ECJ has used the right tool: ordinary people don’t go by this to make buying decisions—buy because they like, not b/c it comes from a particular brand.
 
Graeme Dinwoodie: If in fact you were wrong, why not say it like that?  Why dress it up as empirical.
 
Jacob: we can do that too.
 
Visser: We should do that to recognize the public interest in continued freedom.
 
Martin Senftleben: should we care that much about what we call the consumer/public at all? In practice, there may not be much difference. There are easy cases: Coca-Cola is a well-known mark, which you could know without any survey.  In practice, three surveys say yes and three say no depending on how the questions are designed and analyzed.   “Consumer” is just an argumentation tool. Asking who this consumer is overstretches the whole concept.
 
Marco Ricolfi: A number of provisions in TM law refer to the public.  (RT: Then consistent judicial and academic resort to “consumer” is at least psychologically revealing!)  Underline that this is the case with immoral signs.  Public bears the cost of the immoral sign.
 
Freedom of movement of goods across national borders/unitary system is an important value that also needs to be accounted for.
 
Beebe: What the implications are of speaking in plural versus singular of consumers?  He saw a European fascination w/average consumer as individual: fictional character, asked whether this individual is confused.  US law speaks much more of populations of consumers; bell curve of sophistication. We might look at a mean, but we ask what proportion of this bell curve is confused.
 
Individual rhetoric = licensed to speak more normatively about what this person should think.  Americans with their bell curves are more prone to think of what people actually do think.  Thatcherite slogan: there is no such thing as society. This invariably creates a political effect.
 
Compelling idea: reasonable consumer is more rule-like than standard-like, from Laura Heymann’s article.
 
Davis: what we think competition is differs across time.  Average consumer fits w/neoliberal idea of avoiding as much market regulation as you can.  Underlies current TM law. Given US as archetypal neoclassical economics, it’s interesting that there’s been more resistance to the individual consumer in the US. Why?
 
Austin: are we defining the middle through extreme cases? What if we stripped the consumer out of the discourse and looked at judicial calibration of competition in individual cases? Would we think that the courts were capable of getting that right? Consumer as tool of perceived judicial restraint.  Forensic realities of individual cases: inability to get the kind of data that would allow us to look at true consumer perception.  Plea for a workable approach to these kinds of questions.  Fast-moving case law.
 
David Llewellyn: use of the word consumer is like success of the word “piracy” by © lobbies. Once you choose “consumer” you do put things into a particular box.
 
Mike Grynberg: Use of the consumer as an argumentative tool: dependent on one’s larger views of TM policy. How much can consumer concept constrain the courts or constrain theorists? Not much, except for the idea of consumer as construct v. consumers generally. Some conceptions of consumers are easier to administer from a judicial perspective than others. Some constructs may be more susceptible to racism/sexism than others.  What can we do to go beyond our policy priors?
 
Robin Jacob: Consumer is notat the heart of contemporary TM law; that’s ownership. No consumer oriented favoring system would have decided L’Orealwhere consumers wouldn’t have cared.  There’s a difference in TMs directed at hoi polloi and TMs directed upmarket—luxury/prestige brands get greater protection from the courts, even if the public wouldn’t endorse that.
 
Annette Kur: L’Oreal had to come out that way b/c of the comparative advertising directive.  That directive prohibits presenting something as a replica.  That’s not consumer protection; smuggled in by the French perfumers. TM law is not necessarily going straight towards expansion of protection.
 
Robert Burrell: L’Oreal: you can’t say it’s not TM law; it may not have started that way but it is TM law now. To say it’s an imitation—I didn’t think it was a replica.  (Sir Jacob didn’t think so either.) Idea that ECJ is bound by legislative intent in TM is great, but “goods that are not similar” is not easy to be bound by.
 
Kur: L’Oreal says it’s for the national judge to decide effects on the TM function.
 
Heymann: language we use at least suggests a methodology—“average” suggests empirical/range as opposed to “reasonable” which suggests more normative.
 
TMs as communication from consumer to consumer: communicative function of a particular mark is often that way.  Prescriptive/descriptive debate happens in linguistics generally.
 
Observation effect: much of what we talk about comes about through litigation.  Asking the question in a survey changes the answer you’re likely to get, even in a descriptive mode. Thus move to corpus analysis etc. is a better way to figure out communicative function separate from/prior to litigation and its artificiality.
 
RT: Barton Beebe: The US focus on the bell curve also helps us make more sense of a descriptive fair use defense than perhaps is possible in Europe—what Annette Kur has discussed here as the scope of rights once granted, we would often call descriptive fair use or even non-TM use as in the YSL v. Louboutin case.  Heymann says the use of “average” suggests empirical inquiry: Interestingly we are happy to be normative in describing average consumer (note modification in European cases to average reasonably prudent consumer) and descriptive in identifying the reasonable consumer—if lots of consumers do it it’s probably reasonable.  (Why US is different: Some speculation: Same basic philosophy, different implementation. More openness to separating equilibria among consumers? Readier acceptance of behavioralism?  More openness to preferences as exogenous/it’s ok to like Cheetos, as something that comes from within the consumer as opposed to from an investment by the producer?  Empirical evidence about marketing in general and how it works—might be a response to Graeme Austin’s concern of how much evidence we can really expect to have.)
 
Consumer protection: is it just lower prices? Why isn’t consumer protection also defending quality and class distinction?  There is a strain of argument, at least historically, that it’s bad for consumers to have cheap, degraded versions available to them—replica perfumes, or bread that’s full of preservatives and not freshly made.  That seems like protection to the people who advocate for it.
 
Mid-point summary:   William McGeveran: Themes: (1) Consumer as heuristic, device to get to something else, “coping mechanism” (Gangjee).  That helps explain some of what we see.  “Consumer” as servant to TM’s larger goals. Extent to which public interest ought to be set aside in doing a consumer analysis.  Is public interest extrinsic to that heuristic?  Clearly the heuristic is designed improperly if it’s not serving the goals it’s meant to be serving: the reason to use the heuristic is to get to the ultimate goal. Search costs as mid-level principle, means to an end of competition goals.  Article w/McKenna: “Confusion Isn’t Everything”: confusion is a heuristic in itself for the larger goals of the TM system; could have called it “The Consumer Isn’t Everything.” We could add to the heuristic, or substitute a different heuristic in specific cases. The stakes are high because the concept is so much used, but we should remind judges and ourselves that it’s just a device.
 
(2) Registration: are some doctrines more suited for use of consumers than others?  Consumers’ role in registration and judging infringement.  At least in American structure, infringement inquiry is more likely to be time-sensitive than registration inquiry.  As an American, I’m not that bothered by how consumer is used in registration because that can be sorted out later, though B&B may change that. There’s still room for defenses like descriptive fair use/other phase 2/infringement limits. Maybe that’s not as true in regimes where registration is more important.
 
(3) Totalized consumer: the public/consumers v. a consumer (singular).  How much it was ever possible to find “the” consumer even before scale/crossing national borders. Heymann on the reasonable consumer: even a supposedly monolingual jurisdiction is not monolingual in ways that can be very important to TM law (also cultural references).  Shift of degree rather than kind to look at multinational environment—can no longer be swept under rug.  Finally, Mike Grynberg’s important piece on consumers who are not confused: unfair fight where registrant gets to fight on behalf of consumers, where defendants should be more often allowed to fight on behalf of nonconfused consumers whose interests are furthered by being able to use defendant’s mark as a mark.  “An average consumer” picks sides in a way that might be troubling.
 
Dirk Visser: Is the consumer part of “the people” on whose behalf policy is supposed to be made?  It is very dangerous to go direct to consumers v. representation.  Famous TMs have broader protection—but sometimes fame makes it easier for consumers to distinguish differences. This reasoning threatens the whole edifice, though, so its occasional appearance in European cases is suppressed.  Idea: Unfair to give less protection to famous TM.  (RT: This idea of “less” protection is a signal that we aren’t using the consumer to measure protection as we often claim: if confusion and dilution were really defined by reference to consumer reaction, then consumers who were capable of distinguishing fine differences would provide the famous mark with exactly as much protection as other marks: protection from confusion (and perhaps dilution) which in theory defines the scope of the right.  This claim that we can’t “narrow” protection for strong marks means that we are defining scope in some other way than confusion—relative distinctiveness, as Barton Beebe has written.)
 
Public opinion surveys are always manipulated and judges know that.  They only like it if it’s parallel with their own opinions. We’d rather have an impartial judge who’s familiar with TM law decide, rather than people who can’t be controlled.
 
If it’s a descriptive term, we don’t allow traders to monopolize a term because others may need to use it. Hard to explain to students how secondary meaning through spending a lot of money can be allowed to change that.  Maybe: if other competitors allow you the time to acquire secondary meaning, the need to keep the sign free was not as great, otherwise they would have jumped in. He’s not convinced, but at least that’s some kind of argument.
 
Same reasoning should apply to nontraditional TMs.  European judges don’t like them, especially not shape marks—children’s chair. Have said that the level of distinctiveness is the same for all marks, but also that it’s harder to get over the threshold for nontraditional marks, which sounds ridiculous to an outsider since both those things can’t be true.  We should simply ban nontraditional TMs.  One problem: If we did so, it would go underground and pop up somewhere else under the guise of competition law.  This happens with things like perfume.  Also hyperlinking: if © doesn’t forbid it, they’ll try to use unfair competition law. Some will say fine, then it’s judged case by case. But in a marketplace that might end up the same way (given risk tolerances). TM = perpetual protection, so that’s a very important policy distinction.
 
Martin Senftleben: How can we find out what the consumer really is or wants?  We are already making a normative assumption by combining consumer w/other words like confusion or protection—already paternalistic.  We’d need to say something about consumer without that, which gets philosophical: need a conception of good/better life.
 
Austin?: but that might be a bit too hard.  Heymann claims that language matters: ordinary/reasonable/prudent/average—but those terms are manipulated.  Does calibration of those differences really make a difference to the stories we tell about what’s happened in the market?  Skeptical that we can make the different terms make a difference. 
 
David Llewellyn: One big problem is that judges don’t think about consequences of registration at the infringement level. Practicing for years: people abuse registered TMs. Always write a letter and expect people to give in even though you know you’re overreaching. Allowing these very valuable rights so easily is abused in the real world.  On nontraditional TMs: Visser asks whether it’s better to keep it in the system than allowing passing off.  Whirlpool case is classic example of unregistrable mark made registrable by adding a word that wasn’t really visible in use; that then got a reputation by being sold; then was used to repress competition.
Visser: agrees that kicking them out would create fewer problems. Registration = impresses other people and builds on itself.
 
Kur: there was a time in Germany when German Patent Office was concerned about registering too much because of potential misuse: “need to keep free.”  A terrible time for lawyers!  Repercussions on Court of Justice: strong repulsion against any “need to keep free” echoed what happened in Germany with overuse of that term—a pendulum swinging too far.
 
Kim Weatherall: Giving courts permission to override quantitative evidence may be a good thing.
 
Marco Ricolfi: significant portion of the population?  Tension b/t notion of average consumer and notion of significant portion.  How do we think about this?  Can we divide some issues that should be more normative while others should be empirical?
 
Senftleben: Internet surveys: very cheap ($1000 €) and quick!  May not replicate market conditions, an available criticism, but easy to run. Just a starting point.
 
Ricolfi: the tribunal can say it’s not reliable.
 
Senftleben: yes, there is always a reason to get rid of a survey for not replicating market conditions, time of day, subject population.  But internet survey is fast and cheap.
 
Kur: There is a strong, established place for surveys in Europe w/r/t acquired distinctiveness, but not likely confusion where surveys are rarely accepted, strongly impacted by normative considerations.  (RT: would like to hear more on what those are.)  Survey never tells you exactly the answer on acquired distinctiveness; needs to be weighed.
 
Weatherall: UK and Australia as well: active distinction: reputation surveys are fine, but not confusion.
 
Ohly: even in unfair competition law, there are very few cases in Germany relying on surveys.
 
Andrew Griffiths: consumers as subjects v. objects. As objects: in a market economy, they provide the focal point for attracting demand. Allows people to choose on some basis signified by the TM: accountability. Then we can ask: accountability for what? Usually quality. Mechanism for channeling demand. Consumers are people engaging with the market economy. Vast areas of life previously outside the realm of the consumer have been brought in.
 
TMs and brands are implicated in 2 huge developments: (1) reorganization of production, much outsourcing.  Weightless corporations—retailers, marketing firms.  Consumers have no conception of who produces the products they buy, only of the brand. Huge space between production and consumption. (2) Rise of consumerism/consumer capitalism: huge amount of product differentiation. Consumers, for better or worse, attach value to differentiation/emotional benefits.  Need for greater levels of sophistication in a market economy.  Chinese registration system: student says that consumers are confused about whether registration represents government endorsement.  Led to need to restrict advertising.  People haven’t been programmed as consumers to recognize branding/TM for what they are. 
 
Accountability: Traditionally it was accountability for quality.  Search costs arguments rest on that.  But it can include other things: behavior—corporate social responsibility; supply chains.  (RT: A way of reestablishing the link from production to consumption?  Perhaps only an imaginary one?  A Marxist might identify a human longing for a relation to production.)  Link consumer to citizen—things that we once expected people to react to politically, we now expect them to react to as consumers.  (Which has huge resonances w/gay rights in the US, in many ways, from Chik-Fil-A consumption/boycotting as political expression to the move for “religious freedom” in commercial transactions like employing people and providing services to people.)
 
Gangjee: One way transmissions, left up to TM owner: even in certification marks, there is no accountability to the consumer if the standards are violated. Projection, not conversation.
 
Acquired distinctiveness: pre-litigation surveys. Surveys cause bias; uncertainty/interference w/sample; expense. But if pre-litigation surveys are palatable as RT suggested, then that mediated reality is ok—judges might be more accepting of them.  But how would judges react when the surveys contradict their reactions?
 
Davis: People have gone from “riders” on a train to “consumers” of train services—depoliticized; takes place of engaged participation.
 
Senftleben: Contra Gangjee: large TM owners are worried about what consumers say on Twitter—much more so than about minor litigation.  Taking wrong action against TM parody can cause Twitterstorm that harms the brand/the stock.  Bad publicity has always been possible but can escalate suddenly. Consumer may decide it’s wrong to take action against a certain kind of TM parody, and that’s working.  Reaction against Kit Kat using palm oil/destroying the forest—a parody in which a consumer bit into a Kit Kat and blood came out of it—but acting against it would cause even more negative attention.
 

Greenpeace bleeding Kit Kat ad
Ricolfi: surveys may be suppressed if unfavorable, as with pharmacos that only report favorable results. This is still an important practical question. 
 
Mike Grynberg: Gets to whether we’re talking about the consumer or the public. The consumer is a Swiss Army knife, used to define a lot of aspects of TM.  We need a construction of “consumer,” and certain incarnations are workable.  Average/reasonable consumer can work for confusion at the point of sale, but it’s too narrow when thinking about overarching policy issues of competition, free expression. Judges are boundedly rational, though, and it’s hard to think outside of that construction to broader concerns.
 
Bill McGeveran: We could say: we have a question about TM. Should we look at consumer reaction or at something else? The American system will go ahead and recognize TM rights in lots of nontraditional TMs, and worry downstream about exempting certain kinds of uses. European system may categorically reject some kinds of symbols.  Where we deploy the consumer is a distinct Q from who that consumer is once the decision is made to deploy her.  Sometimes we may simply reject asking the consumer.  (RT: Though it’s super hard for judges to avoid the impulse to say “and the consumer isn’t likely to be confused anyway,” e.g. in cases like Rogers v. Grimaldiwhere there are empirical claims alongside the normative ones.)
 
Graeme Dinwoodie: are there some doctrines that are inappropriate for using consumers in the first instance?  Goods w/which the mark is likely to be used, or goods we’re comfortable giving rights in for a 5 year period to the TM applicant?  Q of whether a mark is identical for purposes of double identity—does that address consumer perception?  One court said yes, and that the consumer should know that if they find it identical then there will be infringement w/o confusion: but why put that in the consumer lens? My sense is that it’s more likely to be inappropriate to invoke the consumer at the registration context.
 
McGeveran: Functionality in the US.
 
Jennifer Davis: aren’t Europeans more likely to take the consumer into account in registration, opposite to what Dinwoodie wants?
 
Dinwoodie: yes for acquired distinctiveness, maybe not elsewhere.
 
Stacey Dogan: Traffix/functionality deals w/ policy issues not endogenous to TM law. Even though the SCt in Dastar purported to make claims about consumer expectations, it was really about the right to copy after a work enters the public domain. Societal interests distinct from market based transactions that sometimes ought to be taken into account.  Bizarre blending of rationales, but deference to ©’s public domain was institutional deference.
 
McGeveran: speech concerns in the US, Rogers v. Grimaldi, explicitly recognizes that we wouldn’t care about confusion if the factors were met.
 
Jessica Litman: Not sure whether this is a shift as opposed to a pendulum, but in past 10 years we’ve seen a backing off from normative considerations to override our sense of empirically what the consumer is about.  Example: scandalousness. At one time, the TTAB would just look at the mark and say it’s scandalous.   Redskins: lots of empirical evidence, and resistance to taking seriously what it showed; but now it seems pretty likely that the Fed. Cir. will say it’s unconstitutional to have that bar in the statute at all; if consumers perceive it as a mark, it’s a mark, and the gov’t lacks any interest in saying that’s inappropriate.  Looks like a retreat from a notion that the public interest has some say in what can be a TM separate from what consumers perceive.
 
Dirk Visser: Fact that © ends is something the public doesn’t understand. Come to believe that everything is licensed (except parody), and the artificial limitation of time is not internalized by them. They could accept it if told, but they wouldn’t have an opinion on it and would assume you need a license for any character T-shirt, whether or not the character was in the public domain.
Barton Beebe: Functionality and genericism (a version of functionality), where courts look to dictionaries; the test can be much more formal than consumer focused, though surveys are also used. Dastar.  Dead presidents: bar on registering name until widow/widower dies.  And the issue of GIs. Even though Americans consider “champagne” generic, the US is going to try to phase it out: imposing on democratic society a hierarchical system, b/c we agreed with the French.  (RT: Should that violate the First Amendment?)  Also the US right of publicity.  Fed court says confusion doesn’t matter; therefore Rogers v. Grimaldi also doesn’t apply b/c right of publicity is about misappropriation.
 
Compare PHOSITA, or more discerning observer in copyright law. Anchor of © is the reader/audience—interesting to consider comparisons. 
 
Eveready survey: do you think the D needed permission from the P for this use? Legal question but we ask it of consumers and courts accept that.
 
Ansgar Ohly: do/should we consider the consumer in questions of use as a trademark? ECJ: TM use is being dissolved and collapsed into the normative “functions” of a TM theory. Moving away from investigating what consumer actually thinks.
 
Acquired distinctiveness: Q arises whether this finding can be corrected by public policy concerns; clash between German and European approaches. German: more public policy concerns = higher distinctiveness required.  ECJ has rejected this time and again; reluctant to get into fact specific investigations of what consumers think, perhaps b/c it’s only in charge of the law.
 
Always market integration is in the back of the mind of the ECJ so the image of the normative European consumer may be a more important referent for them.
 
Kur: but they still insist all these questions are questions of fact that they then hand back to the national courts: a real contradiction.
Posted in consumer protection, http://schemas.google.com/blogger/2008/kind#post, trademark | Leave a comment

Ninth Circuit rejects class certification because ads differed

Cabral v. Supple LLC, — Fed.Appx. —-, 2015 WL 3855142, No. 13–55943 (9th Cir. June 23, 2015)
 
The court of appeals vacated the certification of a class of purchasers of a dietary supplement. The certified class was “[a]ll persons residing in the State of California who purchased [the supplement] for personal use and not for resale since December 2, 2007,” for the usual California statutory claims.  The court of appeals found that predominance was wanting, because it was “critical” that the misrepresentation at issue be made to all class members.  The record here didn’t support a determination that all the class members “saw or otherwise received” the misrepresentation that the supplement was “clinically proven effective in treating joint pain.” “While some deviations from precise wording in the language of advertisements or representations might not be fatal to class certification, advertisements that did not declare the [supplement] to be ‘clinically proven effective in treating joint pain’ are a far cry from advertisements that did.” The court of appeals expressed no opinion on whether a different class could be certified.
Posted in class actions, consumer protection, http://schemas.google.com/blogger/2008/kind#post | Leave a comment

claim of "improved" version of competitor’s product not likely to confuse

Arborjet, Inc. v. Rainbow Treecare Scientific Advancements, Inc., 63 F.Supp.3d 149 (D. Mass. 2014)
 
Arborjet sued Rainbow over an alleged breach of a sales agency agreement and won a preliminary injunction.  Arborjet makes insect and pest control products for direct injection into trees. Rainbow makes pesticides to protect trees and also distributes pesticides manufactured by other companies; it competes directly with Arborjet.
 
In 2008, Arborjet began selling an emamectin benzoate product, TREE-age, which protects trees from the emerald ash borer and other destructive pests. TREE-age was successful, and Rainbow solicited Arborjet to become its distributor of the full line of Arborjet’s products, including TREE-age.  During negotiations, Arborjet allegedly expressed concern about Rainbow’s possible copying of Arborjet’s products, and Rainbow allegedly assured Arborjet that it had no such intention.  So they entered into a Sales Agency Agreement and Rainbow agreed to devote its best efforts to the promotion and sale of Arborjet’s products. 
 
The Agreement included a confidentiality and nondisclosure provision, and said “in view of the confidential information regarding Arborjet’s business affairs, plans, and necessities, [Rainbow] will not engage in affairs intended to replicate the Arborjet’s products or processes.”  Plus, it had a noncompete provision that said Rainbow wouldn’t “replicate the Arborjet system of using a plug which seals the formulation in the xylem and a needle which injects behind the plug” for two years after the agreement ended.  Arborjet didn’t allege a breach of this last provision, but the parties disputed its relevance to Arborjet’s breach of contract claim.
 
Instead, Arborjet alleged that Rainbow violated the part of the agreement prohibiting Rainbow from “engaging in affairs intended to replicate” its products.  Rainbow began developing and testing ArborMectin, its competitor for TREE-age, as early as 2011, when the Agreement was still in force.  (Rainbow terminated the Agreement in 2013.)  Arborjet didn’t allege that Rainbow used confidential information, but said that didn’t matter. 
 
In 2014, Rainbow sent a blast marketing email to customers with the subject line “Improved TREE-age! NEW ArborMectin Speed VIDEO.” The text said that “Rainbow is excited to offer ArborMectin™, an improved 4% emamectin benzoate (TREE-age) tree injection formulation. …Treat trees 30–70% faster using ArborMectin™ versus TREE-age.”  The email linked to a video that characterized ArborMectin as a replacement for TREE-age and indicated that ArborMectin is “backed by science,” “proven to be effective,” and treats trees “consistently faster than TREE-age.”
 
Arborjet argued that, while the Agreement was in effect, Rainbow was contractually barred from engaging in “affairs intended to replicate” Arborjet’s products, even absent misappropriation of Arborjet’s proprietary confidential information. Moreover, Rainbow allegedly breached the implied covenant of good faith and fair dealing given that it knew Arborjet’s purpose in the Agreement was to stop copying.
 
Rainbow argued that it didn’t “replicate” TREE-age because ArborMectin was not a “copy” or “duplicate.” Though the products have the same active ingredient, ArborMectin is less toxic and has lower viscosity than TREE-age. The court found this argument unpersuasive.  First, the fact that the final product had differences didn’t matter, given that the contract covered activities “intended to replicate” Arborject products. Given how Rainbow marketed the product as “improved TREE-age,” the court found its activities covered. Plus, it was unreasonable to read the contract as barring only exact copies “in light of Arborjet’s particular, expressed concern about direct competition with its own products.” Thus there was likely success on the merits of the contract claims.
 
Lanham Act false advertising: Arborjet argued that claims that its product was “backed by science”, “proven effective” and “treats trees 30–70% faster than TREE-age” were establishment claims.  The tests Rainbow relied on were allegedly unreliable because none of them was subject to peer review and the studies tested only five or six trees whereas studies of TREE-age tested between 60 and 100 trees. Thus, the study results didn’t prove the claim that ArborMectin was an improvement over TREE-age. The court found that Arborjet hadn’t demonstrated the studies’ unreliability at this stage, without industry or regulatory standards regarding peer review or sample size.  The claim that ArborMectin was an “improved TREE-age” was a non-establishment claim, just a general claim of superiority. Arborjet didn’t show actual falsity, because ArborMectin had lower toxicity and viscosity than TREE-age and those differences could be regarded as improvements.
 
However, the court expressed concern that the “improved TREE-age” claim was likely to mislead customers into thinking the products came from the same company. Rainbow indicated that it would no longer make that claim.
 
Arborjet also argued that Rainbow’s website infringed Arborjet’s registered trademarks “without including the symbol or any other attribution to the owner,” which would cause customer confusion.  But, as Rainbow pointed out, none of the other confusion factors favored Arborjet, such as the dissimilarity between TREE-age and ArborMectin.  RT: Also, it has never been the rule that failing to use a ® is misleading.  Unfortunately, the court also said that Rainbow “should be more careful with its attribution of proprietary marks in its communications,” even though Arborjet was unlikely to succeed on the merits.  Rainbow should clearly be more careful about suggesting that it produced an “improved version” of someone else’s product—there are lots of ways of saying that which are nonconfusing—but failing to use ® is not one of the ways in which it was careless.
 
Given Arborjet’s substantial likelihood of success on the merits of the contract claim, it had less of a burden to show irreparable harm under the First Circuit’s sliding scale.  The court found irreparable harm because of the significant risk of damage to Arborjet’s reputation and relationships with its consumers.  “Although plaintiff can be compensated for lost profits by monetary damages, the effect on its goodwill and reputation are particularly hard to quantify.”
 
The balance of equities tipped in Arborjet’s favor, but only slightly given Rainbow’s investment in a new product.  Rainbow also argued that the public interest favored competition and that this lawsuit would suppress competition, but “here the parties voluntarily and knowingly contracted to limit their competition.” Thus, it was in the public interest to enforce a limit on competition in this case.
Posted in contracts, http://schemas.google.com/blogger/2008/kind#post, trademark | Leave a comment

False patent marking isn’t material to business customers

Pactiv, LLC v. Multisorb Technologies, Inc., 63 F.Supp.3d 832 (N.D. Ill. 2014)
 
Pactiv and Multisorb compete to sell oxygen absorbers—“packets of chemicals that react with moisture to absorb oxygen when placed inside food containers,” keeping food fresher longer. The parties have sued each other for patent infringement, and Multisorb also counterclaimed for tortious interference and unfair competition and false advertising in violation of the Lanham Act. Pactiv’s patent claims are currently stayed pending re-examination before the PTO.  The court found that prosecution history estoppel barred Multisorb from pursuing its doctrine of equivalents-based patent claim, and therefore Multisorb lost its patent infringement counterclaim.
 
The remaining counterclaims arose from a failed business arrangement with Pactiv. Multisorb agreed to manufacture and sell oxygen absorber packets to Pactiv for use in its fresh meat packaging system, the ActiveTech System. The ActiveTech System is comprised of the ActiveTech Product (the oxygen absorber packet), a “case ready” packaging system, and Pactiv’s methods for packaging products. Shortly after the companies entered into a supply agreement, Pactiv received a patent on a packaging system and a method for sealing and preserving raw meat in a low or reduced oxygen environment. At Pactiv’s request, Multisorb marked the oxygen absorber it supplied with a stamp indicating that the product was protected under the patent.
 
Over ten years later, in 2008, the parties’ business relationship soured after Multisorb began selling oxygen absorbers to Wal-Mart and Wal-Mart vendors directly, taking business from Pactiv. Pactiv switched to Dessicare to make a new oxygen absorber, continuing to mark the Dessicare absorber with the Pactiv patent number.
 
Multisorb charged Pactiv with initiating “sham litigation” against Multisorb with the intention of interfering with its prospective business relationships. Internal Pactiv documents indicated that suing Multisorb had business reasons more than IP-related reasons, and that Pactiv desired to “tie [Multisorb] up” and force it to spend money.  But sham litigation relates to antitrust claims, not tortious interference.  And anyway Multisorb couldn’t prove sham litigation; even assuming Pactiv’s statements indicated bad faith, the court couldn’t find that Pactiv lacked a reasonable chance of success on the merits. Though its patents were recently declared invalid in reexamination (a decision under appeal to the Federal Circuit), there was nothing in the record to show that Pactiv would have known of the invalidity at the time it sued.  Thus, the tortious interference claim failed: “the mere filing of a lawsuit cannot serve as a basis for a tortious interference claim when there has been no showing that the litigant knew or should have known the case was meritless or otherwise unjustified.”
 
As for false marking, Multisorb failed to show that Pactiv intended to deceive the public by marking the oxygen absorber with its patent number.  At best, the evidence showed mere negligence: Pactiv “did not recall any discussions as to what patent number to put on the Desiccare oxygen absorber” and Pactiv “did not have a formal process in place to approve product covers.”
 
As for Multisorb’s Lanham Act counterclaim, Multisorb argued that Pactiv misled customers by telling them that the ActivTech System was protected by a patent when, in fact, it was not. However, Multisorb failed to show deceptiveness or materiality.  “[N]one of the customers deposed in this case indicated that they cared the least bit whether the ActiveTech System was patent protected.”  The Executive VP/COO of one meatpacking company testified that the existence of patents didn’t influence his decision to use Pactiv’s system; the GM of another meatpacking company “testified similarly that patents play no role in its purchasing decisions.”  Another customer witness didn’t recall any discussion of patents relating to the system with Pactiv.  A final customer witness testified that patent protection “didn’t really affect our decision-making process,” and indicated that the validity of the patent wouldn’t have altered its buying process.
Posted in http://schemas.google.com/blogger/2008/kind#post, patent | Leave a comment

London TM finds, food edition

“It’s All About the Base” pizza ad

Chocolate boxes



More chocolate boxes

For the last one, compare this story from Australia about another chocolatier.

from Blogger http://ift.tt/1dmKrwP

Posted in Uncategorized | Tagged , | Leave a comment

London TM finds, food edition

“It’s All About the Base” pizza ad

Chocolate boxes



More chocolate boxes

For the last one, compare this story from Australia about another chocolatier.

Posted in trademark | Leave a comment

it’s illegal to say that use of non-manufacturer accessories voids a warranty

EMED Technologies Corp. 
v. Repro–Med Systems, Inc., No. 13–cv–1957, 2015 WL 3794967 (E.D. Cal. June
16, 2015)
 
The parties compete to supply components of medical devices
used to administer immunoglobulin (human plasma and antibodies) to patients
suffering from a particular immunodeficiency disorder.  This therapy is increasingly administered at
home, instead of in medical offices and hospitals. Ten major customers in the
U.S. purchase the majority of the devices, and EMED and RMS are the two primary
U.S. manufacturers. 
 
The devices relevant to this lawsuit are: (1) mechanical
infusion pumps; (2) rate sets; and (3) subcutaneous needle sets. RMS makes a
Freedom 60 infusion pump, which was cleared by the FDA in 1994 and which has
become the dominant pump in the market. 
Pumps can last 10-15 years, but rate sets and needle sets are single-use
accessories.  Rate sets are a type of
tubing that regulate the flow of infusion between the pump and the needle sets,
and the parties are the only two suppliers of rate sets for use with the
Freedom 60.  EMED developed two different
rate sets: (1) “Infusets,” intended to compete directly with RMS on design and
price; and (2) “VersaRate,” which allow the user to adjust the flow rate. EMED
claimed that Infusets were FDA cleared via 510(k)s from 1994 and May 2014, and
that VersaRate sets were FDA cleared via a 2012 501(k).
 
EMED alleged that RMS tried to push it out of business
through false and misleading statements, including a 2012 “Safety Bulletin” to
customers claiming that when it learned of attempts to “encourage” use of
non-RMS rate sets with the Freedom 60, it was
 
concerned because, to the best of
our knowledge, such knock-off tubing has not been cleared by the FDA for use
with the FREEDOM60 pump, nor tested in accordance with our stringent release
criteria to confirm that it can be safely and effectively used in the RMS FREEDOM60
Syringe Infusion System. RMS believes this knock-off tubing, marketed as the
same product, fails to meet RMS specifications. Furthermore, we believe that
using such non-RMS tubing with the FREEDOM60 Syringe Infusion System could
potentially result in uncontrolled flows that could lead to patient injury or
death.
While RMS investigates whether
legal action against unauthorized sets is necessary to protect customers and
patients, we urge you to use caution and refer to the product labeling …:
Caution: Use only FREEDOM60 tubing
sets manufactured by RMS Medical Products. Use of any other tubing may cause
the syringe to eject from the pump and eventually cause internal damage to the
pump. Use of any other flow rate control tubing set may cause over or under
delivery or medication to the patient, which could result in injury or death.
Please keep in mind that patient
safety may be compromised by the use of unapproved and incompatible flow
control tubing sets to deliver drugs. In addition, regulatory, patent
infringement, reimbursement, and other issues may also arise. Moreover, use of
non-RMS flow rate tubing voids the warranty for the FREEDOM60 Syringe Infusion Pump….
 
RMS’ SEC Form 10-Q in 2013 mentioned the Safety Bulletin and
said that any non-RMS product could be “unsafe” and even cause death.  Its 2014 SEC Form 10-Q said that it didn’t
believe that EMED’s product had FDA clearance. Its website said that it had the
“only tubing specifically designed and FDA-cleared to have the accuracy
necessary for the safe, controlled, dynamically-responsive infusions of the
FREEDOM 60.”  In addition, statements
that use of non-RMS rate sets voids the warranty for the Freedom 60 appeared in
RMS’ four most recent SEC Form 10–Q’s.  And the Freedom 60’s user manual contained a
warranty provision saying that “use with non-approved accessories or disposable
items” voids the warranty.  Similar
statements appeared in a 2014 article on NASDAQ.com and used words like
“knock-off.”
 
EMED alleged that these were false statements that harmed
its sales.  For example, a customer wrote
to EMED stating: “The Freedom 60 warranty is voided if we use sets other than
the RMS products. This is documented in the user manual. Accordingly, the EMED
sets have not been proven to be accurate with the use of the Freedom 60 pump.
Taking these things into consideration, I have asked our locations to
discontinue use of the EMED sets.”  Others expressed concerns about FDA approval
and safety, based on RMS’ claims.  Others
required EMED to indemnify them before agreeing to purchase rate sets.  EMED claimed a loss of roughly 33% in related
revenue since January 2014.
 
RMS sued EMED for patent infringement; EMED counterclaimed
for false advertising.  The court first
found “serious questions going to the merits” (still an alternative to likely
success on the merits in the 9th Circuit).  EMED claimed that, from 2002 to 2005, RMS
contracted with EMED for the “manufacture of microbore tubing for RMS’ branded
rate sets,” and during this time EMED sold at least 155,000 units of microbore
tubing to RMS. RMS provided EMED with specifications necessary to manufacture
the tubing, which allowed EMED to specifically design its rate sets for the
Freedom 60 pump.  For years, RMS
allegedly provided consumers with instructions for using EMED needle sets.
Thus, the claim that EMED accessories couldn’t be used with RMS products was
false.

RMS responded that, before issuing its Safety Bulletin, RMS tested EMED’s
products and found that EMED’s Infuset products did not provide flow rates that
are compatible with the advertised RMS equivalent.  RMS argued that EMED tested its products
improperly, using fluids of the wrong viscosity.  EMED never made complete tubing sets, and
thus didn’t have the complete specifications. 
RMS attributed EMED’s revenue decline to RMS’ ability to sell a total
system for treating patients. 
 
The court found that the facts were disputed as to whether
EMED’s testing procedures were equivalent to RMS’, or whether the alleged
superiority of RMS’ “total system” was the reason for EMED’s decline in
revenue.
 
So what about those 510(k)s? 
A 510(k) clearance means that there’s substantial equivalence to another
legally marketed device, with either the same technological characteristics or
differences that don’t raise new questions of safety and effectiveness.  EMED’s 2012 clearance didn’t specifically
mention the Freedom 60, but the May 2014 clearance for Infusets did.  Internal EMED emails, construed in a light
favorable to RMS, showed doubt over whether EMED previously had FDA clearance,
though EMED’s position was that its VersaRate clearance covered a variety of
pumps, including the Freedom 60; the court couldn’t make a definitive finding
at this time, or a definitive finding that Infusets were covered by the 1994
510(k), even though RMS’ argument that Infusets weren’t covered was “unconvincing.” 
 
However, it was undisputed that there was clearance for
Infusets to be used with the Freedom 60 as of May 2014. After that time, the
Safety Bulletin warning of “death” was still available on RMS’ website, and
showed up as the top Google search entry when typing in “Freedom60 customers.”
It wasn’t clear how much RMS participated in the NASDAQ.com article, but the
article tracked the statements in the Safety Bulletin, and those statements
were false or misleading, because they contradict the fact that Infusets were
FDA cleared to be used safely with the Freedom 60.  Likewise, as of September 2014, the RMS
website still said “That’s why it has to be Precision—it’s the only tubing
specifically designed and FDA-cleared to have the accuracy necessary for the
safe, controlled, dynamically-responsive infusions of the FREEDOM 60.” RMS
argued that even if Infusets received FDA clearance they still were not FDA
cleared and designed for accuracy
with the Freedom 60. Still, it was misleading in light of the 510(k). The court
found that EMED raised serious questions going to the merits on falsity and
misleadingness as of May 2014.
 
In addition, EMED argued that RMS’ claims about voiding the
warranty violated the Magnuson–Moss Act, Section 2302(c) of which states:
 
No warrantor of a consumer product
may condition his written or implied warranty of such product on the consumer’s
using, in connection with such product, any article or service (other than
article or service provided without charge under the terms of the warranty)
which is identified by brand, trade, or corporate name …
 
Comment: News to me! 
That is a very interesting provision, and I wonder if it’s
underlitigated compared to other claims. 
RMS said EMED didn’t have standing to enforce the law, which permits
suits by the AG, the FTC, and consumers. 
But California’s UCL converts violations of other laws into violations
of the UCL, and RMS was allowed to sue under the UCL.
 
RMS argued that it didn’t know about the law, but that doesn’t
change the fact that voiding the Freedom 60’s warranty based on use of non-RMS
products would actually violate the Magnuson–Moss Act.  The Safety Bulletin thus described an unlawful
warranty, apparently directed specifically at EMED, which again raised serious
questions going to the merits of a claim for “unfair or fraudulent” practices
or “unfair, deceptive, untrue, or misleading advertising.”
 
Turning to the remaining preliminary injunction factors: RMS
argued that EMED had unclean hands because a draft user manual for its products
had the same provision, but that was just a draft. The current user manual
states: “Limited Warranty: EMED Technologies Corporation (“Manufacturer”)
warrants the SCIg60 Infuser to be free from defects in materials and
workmanship under normal use.”
 
The balance of hardships tipped “sharply” in EMED’s favor,
given the evidence of negative customer response, indemnity agreements demanded
by customers, and declining revenues. 
Enjoining RMS to stop its false or misleading statements would cause
minimal to no hardship.
 
RMS argued that EMED’s delay in seeking a preliminary
injunction cut against a finding of irreparable harm.  EMED waited for nearly two years to use after
receiving December 2012 customer emails expressing concerns; it waited over 16
months after sending its first cease-and-desist letter to RMS and one year
aftter sending its second; and it waited 11 months after asserting its
counterclaims. EMED argued that it acted after RMS continued to claim that only
its products could be safely used with the Freedom 60 even after the May 2014
510(k).  The court agreed that the delay
was long, given EMED’s position that its rate sets were FDA cleared even before
May 2014, but delay is just a single factor and courts are reluctant to
withhold relief solely on this ground.
 
EMED supported its irreparable harm claim with evidence that
the Safety Bulletin raised customer concerns about safety and voiding the
warranty, plus allegations of lost revenue. 
Given all this, an injunction against false and misleading advertising
was in the public interest.

from Blogger http://ift.tt/1Jo5PAd

Posted in Uncategorized | Tagged , | Leave a comment